Log in

OTCMKTS:QBIOQ BioMed Stock Price, Forecast & News

$1.60
-0.03 (-1.84 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.55
Now: $1.60
$1.65
50-Day Range
$1.63
MA: $1.83
$1.99
52-Week Range
$0.34
Now: $1.60
$3.75
Volume78,575 shs
Average Volume79,379 shs
Market Capitalization$36.24 million
P/E RatioN/A
Dividend YieldN/A
Beta2.56
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; BM-001 for the treatment of rare pediatric nonverbal autism spectrum disorder; and Uttroside-B for liver cancer. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was founded in 2013 and is based in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.65 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:QBIO
Previous SymbolNASDAQ:QBIO
CUSIPN/A
Phone212-588-0022

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.26) per share

Profitability

Net Income$-10,280,000.00

Miscellaneous

Employees1
Market Cap$36.24 million
Next Earnings Date7/16/2020 (Estimated)
OptionableNot Optionable

Receive QBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for QBIO and its competitors with MarketBeat's FREE daily newsletter.

Q BioMed (OTCMKTS:QBIO) Frequently Asked Questions

How has Q BioMed's stock been impacted by COVID-19 (Coronavirus)?

Q BioMed's stock was trading at $1.5728 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, QBIO stock has increased by 1.7% and is now trading at $1.60. View which stocks have been most impacted by Coronavirus.

When is Q BioMed's next earnings date?

Q BioMed is scheduled to release its next quarterly earnings announcement on Thursday, July 16th 2020. View our earnings forecast for Q BioMed.

How were Q BioMed's earnings last quarter?

Q BioMed Inc (OTCMKTS:QBIO) issued its quarterly earnings results on Monday, April, 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.13. View Q BioMed's earnings history.

Has Q BioMed been receiving favorable news coverage?

News articles about QBIO stock have been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Q BioMed earned a media sentiment score of 1.9 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Q BioMed.

Who are some of Q BioMed's key competitors?

What other stocks do shareholders of Q BioMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Q BioMed investors own include Washington Trust Bancorp (WASH), Micron Technology (MU), NVIDIA (NVDA), Otonomy (OTIC), Canopy Growth (CGC), New Age Beverages (NBEV), Opko Health (OPK), Adobe (ADBE), Advanced Micro Devices (AMD) and Cyberark Software (CYBR).

Who are Q BioMed's key executives?

Q BioMed's management team includes the following people:
  • Mr. Denis D. Corin, Chairman, CEO, Pres & CFO (Age 46)
  • Mr. William S. Rosenstadt, Gen. Counsel & Director (Age 51)
  • Mr. David Laskow-Pooley, VP of Product Devel. (Age 65)
  • Mr. Robert Derham, VP of Orphan Products
  • Mr. Ari Jatwes, Bus. Devel. Analyst

What is Q BioMed's stock symbol?

Q BioMed trades on the OTCMKTS under the ticker symbol "QBIO."

How do I buy shares of Q BioMed?

Shares of QBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Q BioMed's stock price today?

One share of QBIO stock can currently be purchased for approximately $1.60.

How big of a company is Q BioMed?

Q BioMed has a market capitalization of $36.24 million. Q BioMed employs 1 workers across the globe.

What is Q BioMed's official website?

The official website for Q BioMed is www.qbiomed.com.

How can I contact Q BioMed?

Q BioMed's mailing address is 366 MADISON AVENUE 3RD FLOOR, NEW YORK NY, 10017. The company can be reached via phone at 212-588-0022.

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.